ICG 1
ICG 1 is a small molecule inhibitor that targets Wnt/β-catenin pathway. It inhibits TCF/β-catenin mediated transcription by competing with β-catenin for CBP (CREB binding protein) but not p300 binding with an IC50 of 3 µM. It can be used to specifically evaluate the role of CBP/beta-catenin association on WNT signaling and cell physiology.
Product Specifications
Background
ICG001 selectively inhibits colon carcinoma cell lines (SW480 and HCT-116 cells) but not normal colonic epithelial cells (CCD-841Co) . It is also efficacious in the Min mouse and nude mouse xenograft models of colon cancer. ICG-001 is a potent inhibitor of GBM stem cells in culture. ICG001 selectively inhibits Wnt/beta-catenin/CREB binding protein (CBP) signaling to reverses pulmonary fibrosis and ameliorate experimental dermal fibrosis in experimental models. ICG001 is currently in clinical trials for colon cancer and leukemias.
Purity
≥ 98%
Solubility
≥ 27.43 mg/mL in DMSO; insoluble in H2O; ≥ 35.47 mg/mL in EtOH with ultrasonic. For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while.
Molecular Formula
C33H32N4O4
Shipping Conditions
Room Temperature (continental US) or Gel Packs
Storage Conditions
Store at or below –20°C. Solid form is stable at least 12 months from date of receipt, when stored as directed. Do not store aqueous solutions for more than one day.
Calculated Molecular Weight
548.63 Da
CAS Number
847591-62-2
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
